A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
April 13th, 2018
11.2K views
We describe a non-invasive multimodal imaging approach based on Micro-CT and fluorescence molecular tomography for longitudinal assessment of the mouse lung fibrosis model induced by double intratracheal instillation of bleomycin.
Overview
This study presents a non-invasive multimodal imaging approach utilizing Micro-CT and fluorescence molecular tomography (FMT) for the longitudinal assessment of lung fibrosis in a mouse model. The method allows for the monitoring of anatomical changes and specific molecular events associated with lung fibrosis over time.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Medical Imaging
Background
- Lung fibrosis is a progressive disease that can be modeled in mice.
- Current imaging techniques often require invasive procedures.
- Non-invasive imaging can enhance the understanding of disease progression.
- Combining FMT with Micro-CT offers a comprehensive view of lung changes.
Purpose of Study
- To longitudinally monitor lung fibrosis in an IPF-like mouse model.
- To assess the effectiveness of non-invasive imaging techniques.
- To study the progression of lung fibrosis and evaluate new therapies.
Methods Used
- Micro-CT imaging for anatomical assessment.
- Fluorescence molecular tomography for molecular event tracking.
- Double intratracheal instillation of bleomycin to induce fibrosis.
- Monitoring of anesthetized mice during imaging procedures.
Main Results
- Successful non-invasive monitoring of lung fibrosis progression.
- Identification of specific molecular events associated with fibrosis.
- Demonstrated advantages of combined imaging techniques.
- Potential applications in evaluating therapies for IPF.
Conclusions
- The multimodal imaging approach is effective for studying lung fibrosis.
- Non-invasive techniques can provide insights into disease mechanisms.
- This method may facilitate the development of new therapeutic strategies.
Frequently Asked Questions
What is the significance of using non-invasive imaging?
Non-invasive imaging allows for repeated assessments without harming the animal, providing a clearer picture of disease progression.
How does the combination of FMT and Micro-CT enhance research?
The combination provides both anatomical and molecular insights, allowing for a more comprehensive understanding of lung fibrosis.
What model is used in this study?
An IPF-like mouse model is used to study lung fibrosis induced by bleomycin.
What are the potential applications of this research?
The findings may aid in the evaluation of new therapies for idiopathic pulmonary fibrosis (IPF).
What imaging techniques are employed in this study?
Micro-CT and fluorescence molecular tomography (FMT) are the primary imaging techniques used.
How does bleomycin induce lung fibrosis in mice?
Bleomycin is administered via intratracheal instillation, leading to lung injury and subsequent fibrosis.
Executive Industry Relevance
Non-invasive longitudinal imaging of lung fibrosis addresses a critical gap in preclinical IPF research by enabling repeated assessments without terminal procedures. This multimodal approach supports mechanistic de-risking by correlating molecular events with anatomical changes, improving predictive confidence in target validation. The method enhances translational continuity from discovery through preclinical evaluation, reducing late-stage biological risk in antifibrotic programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by tracking molecular events and anatomical progression in IPF-like models.
- Operational Value: Provides quantitative, reproducible readouts for pathway clarification and functional target validation.
- Strategic Value: Supports predictive confidence and portfolio triage through longitudinal disease severity monitoring.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream workflows by establishing baseline fibrosis progression.
- Operational Value: Delivers standardized, quantitative imaging outputs suitable for assay reproducibility and scalability.
- Strategic Value: Enhances screening readiness by enabling reliable compound evaluation in longitudinal studies.
Translational & Preclinical Research
- Scientific Value: Aligns with disease relevance by modeling IPF pathogenesis through bleomycin-induced fibrosis.
- Operational Value: Ensures continuity from discovery through preclinical validation via repeated non-invasive imaging.
- Strategic Value: Informs risk-adjusted advancement decisions by providing longitudinal fibrosis quantification.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from Early Discovery to Lead Identification and Preclinical work by enabling hypothesis testing, pathway clarification, and quantitative disease monitoring.
- Discovery Biology: Supports hypothesis testing and pathway clarification by linking molecular events to anatomical changes in lung fibrosis.
- Screening: Provides assay readiness through reproducible, quantitative imaging of fibrosis progression over time.
- Analytics: Generates measurable outputs such as airway radius and fluorescence quantification to compare experimental conditions.
- Translational Research: Connects to preclinical continuity by enabling longitudinal monitoring that mirrors clinical disease progression.
- Enterprise Reuse: Functions as a reusable imaging platform for antifibrotic therapy evaluation across multiple study cycles.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence, target validation, reduction of mechanistic ambiguity in fibrosis mechanisms.
- Operational Value: Standardization, reproducibility, and scalability of non-invasive imaging across timepoints.
- Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk in IPF programs.
- Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on longitudinal fibrosis data.
Implementation Considerations
- Requires expertise in small animal imaging, anesthesia, and intravenous probe delivery.
- Depends on Micro-CT and FMT instrumentation with associated software for image acquisition and quantification.
- Necessitates cross-team standardization for consistent imaging protocols and data analysis.
- Involves adaptation considerations for different model systems and probe chemistries.
- Limited by the need for specialized equipment and operator training, as noted in the procedural workflow.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in lung fibrosis imaging?
Null hypothesis testing determines whether observed changes in fibrosis metrics, such as airway radius or fluorescence signal, are statistically significant compared to controls. This ensures that target engagement or therapeutic effects are not due to random variation, supporting confident target validation decisions.
How does independent variable isolation fit the discovery pipeline in multimodal fibrosis imaging?
Isolating independent variables like bleomycin dose or compound treatment allows researchers to attribute changes in molecular or anatomical readouts to specific interventions. This clarity is essential for identifying valid targets and de-risking hypotheses early in the discovery pipeline.
What quantitative dependent variable measurements enable longitudinal fibrosis assessment?
Quantitative measurements such as airway radius segmentation and fluorescence picomole quantification enable objective tracking of fibrosis progression over time. These outputs provide the numerical basis for comparing conditions and evaluating therapeutic efficacy in longitudinal studies.
Why do replication requirements matter for cross-functional collaboration in imaging studies?
Replication ensures that imaging results are consistent across animals and experiments, which is critical for building confidence in data shared between discovery, preclinical, and translational teams. Reliable replication supports unified decision-making and reduces variability in multi-site or cross-functional projects.
What statistical analysis capabilities are required before implementing longitudinal fibrosis imaging?
Implementation requires capabilities for longitudinal data analysis, including repeated measures ANOVA or mixed-effects models to account for within-animal correlation over time. Additionally, threshold-based significance testing is needed to determine meaningful changes in fibrosis metrics such as airway size or molecular signal intensity.
Chapters in this video
0:04
Title
0:56
Intratracheal Administration of Bleomycin
1:46
Probe Injection for Fluorescence Molecular Tomography
2:25
Fluorescence Molecular Tomography Imaging
3:45
In Vivo Imaging by Micro-CT
5:45
Results: Time-course and Quantification of Bleomycin-induced Lung Fibrosis
7:09
Conclusion
